An effective HIV vaccine must elicit immune responses that recognize genetically diverse viruses. It must generate CD8+ T lymphocytes that control HIV replication and CD4+ T lymphocytes that provide help for the generation and maintenance of both cellular and humoral immune responses against the virus. Creating immunogens that can elicit cellular immune responses against the genetically varied circulating isolates of HIV presents a key challenge for creating an HIV vaccine. Polyvalent mosaic immunogens derived by in silico recombination of natural strains of HIV are designed to induce cellular immune responses that recognize genetically diverse circulating virus isolates8. Here we immunized rhesus monkeys by plasmid DNA prime and recombinan...
Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV. Plas...
The development of an effective human immunodeficiency virus type 1 (HIV-1) vaccine is the best solu...
AbstractWe developed an AIDS vaccine for Western and West-Central Africa founded on HIV-1 subtype CR...
An effective HIV vaccine must elicit immune responses that recognize genetically diverse viruses1, 2...
To create an HIV-1 vaccine that generates sufficient breadth of immune recognition to protect agains...
The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development. Antige...
An effective human immunodeficiency virus type 1 (HIV-1) vaccine must induce protective antibody res...
AbstractTo create an HIV-1 vaccine that generates sufficient breadth of immune recognition to protec...
The biggest roadblock in development of effective vaccines against human immunodeficiency virus type...
Polyvalent mosaic HIV immunogens offer a potential solution for generating vaccines that can elicit ...
SummaryThe global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine developmen...
The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-...
Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that ...
One of the major challenges that must be met in developing an HIV-1 vaccine is devising a strategy t...
Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that ...
Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV. Plas...
The development of an effective human immunodeficiency virus type 1 (HIV-1) vaccine is the best solu...
AbstractWe developed an AIDS vaccine for Western and West-Central Africa founded on HIV-1 subtype CR...
An effective HIV vaccine must elicit immune responses that recognize genetically diverse viruses1, 2...
To create an HIV-1 vaccine that generates sufficient breadth of immune recognition to protect agains...
The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development. Antige...
An effective human immunodeficiency virus type 1 (HIV-1) vaccine must induce protective antibody res...
AbstractTo create an HIV-1 vaccine that generates sufficient breadth of immune recognition to protec...
The biggest roadblock in development of effective vaccines against human immunodeficiency virus type...
Polyvalent mosaic HIV immunogens offer a potential solution for generating vaccines that can elicit ...
SummaryThe global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine developmen...
The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-...
Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that ...
One of the major challenges that must be met in developing an HIV-1 vaccine is devising a strategy t...
Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that ...
Induction of HIV-specific T-cell responses by vaccines may facilitate efficient control of HIV. Plas...
The development of an effective human immunodeficiency virus type 1 (HIV-1) vaccine is the best solu...
AbstractWe developed an AIDS vaccine for Western and West-Central Africa founded on HIV-1 subtype CR...